News

The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the

The positive top-line results from the trial showed the treatment effect of axicabtagene ciloleucel in a patient population of 101 having multiple types of aggressive NHL, said Kite

EMD Serono is the biopharmaceutical business of Merck in the US and Canada. The BLA has been accepted for Merck and Pfizer's avelumab to treat patients with locally advanced or mUC with

The $30m funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and Israeli biotechnology investors,

Advaxis’ proprietary technology generates innate immune stimulation, alongside potent and sustained T-cell responses. When combined with Sellas’ WT1 antigens, this has the potential to precisely direct an immune

In the phase 3 trial dubbed ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) in 344 catecholamine resistant hypotension patients, LJPC-501 demonstrated positive top-line results. The percentage

The companies will establish a joint venture (JV) and each share equally in the initial investment. Subject to necessary regulatory approvals, the construction on the initial phase of the facility

If approved, Tafinlar + Mekinist will be the first targeted treatment available for patients with BRAF V600-positive NSCLC. Of the estimated 1.8 million new cases of lung cancer

A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology